Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity

Pharmacogenomics

Volumn 8, Issue 5, 2007, Pages 435-442

  Ueda, Kentaro ^a   Ishitsu, Takateru ^b   Seo, Takayuki ^a   Ueda, Nao ^c   Murata, Tsukasa ^a   Hori, Masaharu ^a   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Saishunsou National Hospital   (Japan)

^c KUMAMOTO CHUO HOSPITAL   (Japan)

Author keywords

Carbamazepine; Epilepsy; Glutathione S transferase; Hepatotoxicity; Microsomal epoxide hydrolase; Polymorphisms

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DNA; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; PHENOBARBITAL; PHENYTOIN; TROGLITAZONE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FEVER; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MYDRIASIS; NORMAL VALUE; POLYMERASE CHAIN REACTION; RASH; RISK FACTOR; SIDE EFFECT; VOMITING;

ADOLESCENT; ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE; MOLECULAR SEQUENCE DATA; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 34248582562     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.5.435     Document Type: Article

References (35)

1. Brodie MJ, Dichter M: Antiepileptic drugs. N. Engl. J. Med. 334(3), 168-175 (1996).
2. Kalapos MP: Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. Adverse Drug React. Toxicol. Rev. 21(3), 123-141 (2002).
3. Pearce RE, Uetrecht JP, Leeder JS: Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab. Dispos. 33(12), 1819-1826 (2005).
4. Pearce RE, Vakkalagadda GR, Leeder JS: Pathways of carbamazepine bioactivation in vitro I. Characterization of huma cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos. 30(11). 1170-1179 (2002).
5. Lertratanangkoon K, Horning MG: Metabolism of carbamazepine. Drug Metab. Dispos. 10(1), 1-10 (1982).
6. Pelkonen O, Myllynen P, Taavitsainen P et al.: Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31(6), 321-343 (2001).
7. Bu HZ, Kang P, Deese AJ et al.: Human in vitro glutathionyl and protein adducts of carbamazepine-10.11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab. Dispos. 33(12), 1920-1924 (2005).
8. Pirmohamed M, Kitteringham NR, Guenthner TM et al.: An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol. 43(8), 1675-1682 (1992).
9. Hayes JD, Flanagan JU, Jowsey IR: Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45, 51-88 (2005).
10. Eaton DL, Bammler TK: Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol. Sci. 49(2), 156-164 (1999).
11. Munaka M, Kohshi K, Kawamoto T et al.: Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 129(6), 355-360 (2003).
12. Lin HJ, Han CY, Bernstein DA et al.: Ethnic distribution of the glutathione transferase μ1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 15(5), 1077-1081 (1994).
13. Fretland AJ, Omiecinski CJ: Epoxide hydrolases: biochemistry and molecular biology. Chem. Biol. Interact. 129(1-2), 41-59 (2000).
14. Nakajima Y. Saito Y, Shiseki K et al.: Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10, 11-epoxide in Japanese epileptic patients. Eur. J. Clin. Pharmacol. 61(1), 25-34 (2005).
15. Navarro VJ, Senior JR: Drug-related hepatotoxicity. N. Engl. J. Med. 354(7), 731-739 (2006).
16. Kaplowitz N: Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4(6). 489-499 (2005).
17. Watanabe I, Tomita A, Shimizu M et al.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73(5), 435-455 (2003).
18. Richards B, Skoletsky J, Shuber AP et al.: Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet. 2(2), 159-163 (1993).
19. Sarmanova J, Benesova K, Gut I et al.: Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum. Mol. Genet. 10(12). 1265-1273 (2001).
20. Ye S, Dhillon S, Ke X et al.: An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29(17), E88-E88 (2001).
21. Sarmanova J. Tynkova L. Susova S et al.: Genetic polymorphisms of biotransformation enzymes: allele frequencies in the population of the Czech Republic. Pharmacogenetics 10(9). 781-788 (2000).
22. Benichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 11(2). 272-276 (1990).
23. Garcia-Closas M. Malats N, Silverman D et al.: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486), 649-659 (2005).
24. d'Errico A, Malats N, Vineis P et al.: Review of studies of selected metabolic polymorphisms and cancer. IARC Sci. Publ. 148, 323-393 (1999).
25. Roy B, Chowdhury A, Kundu S et al.: Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J. Gastroenterol. Hepatol. 16(9), 1033-1037 (2001).
26. Simon T, Becquemont L. Mary-Krause M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 67(4), 432-437 (2000).
27. Masubuchi N, Makino C, Murayama C. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 20(3), 455-464 (2007).
28. Lillibridge JH, Amore BM, Slattery JT et al.: Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab. Dispos. 24(5). 509-514 (1996).
29. Seo T, Nakada N, Ueda N et al.: Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin. Pharmacol. Ther. 79(5). 509-510 (2006).
30. Patsalos PN, Perucca E: Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2(8), 347-356 (2003).
31. Ono H, Sakamoto A. Sakura N: Plasma total glutathione concentrations in epileptic patients taking anticonvulsants. Clin. Chim. Acta 298(1-2), 135-143 (2000).
32. Ahmed SN, Siddiqi ZA: Antiepileptic drugs and liver disease. Seizure 15(3), 156-164 (2006).
33. Gaedigk A, Spielberg SP, Grant DM: Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4(3), 142-153 (1994).
34. Hassett C, Aicher L, Sidhu JS et al.: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet. 3(3), 421-428 (1994).
35. Watkins PB, Seeff LB: Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43(3), 618-631 (2006).